Difference between revisions of "Pancreatic cancer - historical"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "'''contains dosing details in abstract'''" to "'''dosing details in abstract have been reviewed by our editors'''") |
||
(13 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
− | The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only | + | The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the [[Pancreatic_cancer|main pancreatic cancer page]] for current regimens. |
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
Line 9: | Line 9: | ||
==FLEC {{#subobject:a6c123|Regimen=1}}== | ==FLEC {{#subobject:a6c123|Regimen=1}}== | ||
FLEC: '''<u>F</u>'''luorouracil, '''<u>L</u>'''eucovorin (Folinic acid), '''<u>E</u>'''pirubicin, '''<u>C</u>'''arboplatin | FLEC: '''<u>F</u>'''luorouracil, '''<u>L</u>'''eucovorin (Folinic acid), '''<u>E</u>'''pirubicin, '''<u>C</u>'''arboplatin | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#ee6b6e"> |
===Regimen {{#subobject:ac72e0|Variant=1}}=== | ===Regimen {{#subobject:ac72e0|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
! style="width: 20%" |Study | ! style="width: 20%" |Study | ||
− | ! style="width: 20%" | | + | ! style="width: 20%" |Dates of enrollment |
! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
! style="width: 20%" |Comparator | ! style="width: 20%" |Comparator | ||
Line 22: | Line 22: | ||
| style="background-color:#1a9851" |Phase 3 (E-esc) | | style="background-color:#1a9851" |Phase 3 (E-esc) | ||
|[[Pancreatic_cancer#Gemcitabine_monotherapy_2|Gemcitabine]] | |[[Pancreatic_cancer#Gemcitabine_monotherapy_2|Gemcitabine]] | ||
− | | style="background-color:#91cf60" |Seems to have superior OS | + | | style="background-color:#91cf60" |Seems to have superior OS (primary endpoint) |
|- | |- | ||
|} | |} | ||
<div class="toccolours" style="background-color:#b3e2cd"> | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Fluorouracil (5-FU)]] | + | *[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup> IA bolus once on day 1 |
− | *[[Folinic acid | + | *[[Leucovorin (Folinic acid)]] 100 mg/m<sup>2</sup> IA bolus once on day 1 |
− | *[[Epirubicin (Ellence)]] | + | *[[Epirubicin (Ellence)]] 60 mg/m<sup>2</sup> IA bolus once on day 1 |
− | *[[Carboplatin (Paraplatin)]] | + | *[[Carboplatin (Paraplatin)]] 300 mg/m<sup>2</sup> IA bolus once on day 1 |
+ | '''21-day cycle for 3 cycles''' | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | #Cantore M, Fiorentini G, Luppi G, Rosati G, Caudana R, Piazza E, Comella G, Ceravolo C, Miserocchi L, Mambrini A, Del Freo A, Zamagni D, Rabbi C, Marangolo M. Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology. J Chemother. 2004 Dec;16(6):589-94. [https://doi.org/10.1179/joc.2004.16.6.589 link to original article] [https://pubmed.ncbi.nlm.nih.gov/15700852 PubMed] | + | #Cantore M, Fiorentini G, Luppi G, Rosati G, Caudana R, Piazza E, Comella G, Ceravolo C, Miserocchi L, Mambrini A, Del Freo A, Zamagni D, Rabbi C, Marangolo M. Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology. J Chemother. 2004 Dec;16(6):589-94. [https://doi.org/10.1179/joc.2004.16.6.589 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/15700852/ PubMed] |
+ | |||
=Metastatic disease, first-line= | =Metastatic disease, first-line= | ||
==PEFG {{#subobject:f0e123|Regimen=1}}== | ==PEFG {{#subobject:f0e123|Regimen=1}}== | ||
PEFG: '''<u>P</u>'''latinol (Cisplatin), '''<u>E</u>'''pirubicin, '''<u>F</u>'''luorouracil, '''<u>G</u>'''emcitabine | PEFG: '''<u>P</u>'''latinol (Cisplatin), '''<u>E</u>'''pirubicin, '''<u>F</u>'''luorouracil, '''<u>G</u>'''emcitabine | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#ee6b6e"> |
===Regimen {{#subobject:5d6ee0|Variant=1}}=== | ===Regimen {{#subobject:5d6ee0|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
− | !style="width: 20%"| | + | !style="width: 20%"|Dates of enrollment |
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 20%"|Comparator | !style="width: 20%"|Comparator | ||
Line 49: | Line 51: | ||
|2000-2003 | |2000-2003 | ||
| style="background-color:#1a9851" |Phase 3 (E-esc) | | style="background-color:#1a9851" |Phase 3 (E-esc) | ||
− | |[[Pancreatic_cancer# | + | |[[Pancreatic_cancer#Gemcitabine_monotherapy_5|Gemcitabine]] |
− | | style="background-color:# | + | | style="background-color:#1a9850" |Superior PFS4 (primary endpoint)<br>PFS4: 60% vs 28%<br>(HR 0.46, 95% CI 0.26-0.79) |
|- | |- | ||
|} | |} | ||
Line 62: | Line 64: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | #Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli L, Bordonaro R, Passardi A, Zerbi A, Balzano G, Aldrighetti L, Staudacher C, Villa E, Di Carlo V. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol. 2005 Jun;6(6):369-76. [https://doi.org/10.1016/S1470-2045(05)70175-3 link to original article] ''' | + | #Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli L, Bordonaro R, Passardi A, Zerbi A, Balzano G, Aldrighetti L, Staudacher C, Villa E, Di Carlo V. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol. 2005 Jun;6(6):369-76. [https://doi.org/10.1016/S1470-2045(05)70175-3 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/15925814/ PubMed] |
+ | |||
=Metastatic disease, all lines of therapy= | =Metastatic disease, all lines of therapy= | ||
==SMF {{#subobject:f7dcb5|Regimen=1}}== | ==SMF {{#subobject:f7dcb5|Regimen=1}}== | ||
SMF: '''<u>S</u>'''treptozotocin, '''<u>M</u>'''itomycin, 5-'''<u>F</u>'''luorouracil | SMF: '''<u>S</u>'''treptozotocin, '''<u>M</u>'''itomycin, 5-'''<u>F</u>'''luorouracil | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#ee6b6e"> |
===Regimen {{#subobject:251b74|Variant=1}}=== | ===Regimen {{#subobject:251b74|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
− | !style="width: 20%"| | + | !style="width: 20%"|Dates of enrollment |
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 20%"|Comparator | !style="width: 20%"|Comparator | ||
Line 78: | Line 81: | ||
|1987-1989 | |1987-1989 | ||
| style="background-color:#1a9851" |Phase 3 (C) | | style="background-color:#1a9851" |Phase 3 (C) | ||
− | |[[# | + | |[[#CAC_999|CAC]] |
| style="background-color:#1a9850" |Superior OS | | style="background-color:#1a9850" |Superior OS | ||
|- | |- | ||
Line 84: | Line 87: | ||
<div class="toccolours" style="background-color:#b3e2cd"> | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Streptozocin (Zanosar)]] | + | *[[Streptozocin (Zanosar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1, 8, 29, 36 |
− | *[[Mitomycin (Mutamycin)]] | + | *[[Mitomycin (Mutamycin)]] 10 mg/m<sup>2</sup> IV once on day 1 |
− | *[[Fluorouracil (5-FU)]] | + | *[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once per day on days 1, 8, 29, 36 |
+ | '''8-week cycles''' | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | #Kelsen D, Hudis C, Niedzwiecki D, Dougherty J, Casper E, Botet J, Vinciguerra V, Rosenbluth R. A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer. 1991 Sep 1;68(5):965-9. [https://doi.org/10.1002/1097-0142(19910901)68:5%3C965::aid-cncr2820680509%3E3.0.co;2-2 link to original article] [https://pubmed.ncbi.nlm.nih.gov/1833042/ PubMed] | + | #Kelsen D, Hudis C, Niedzwiecki D, Dougherty J, Casper E, Botet J, Vinciguerra V, Rosenbluth R. A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer. 1991 Sep 1;68(5):965-9. [https://doi.org/10.1002/1097-0142(19910901)68:5%3C965::aid-cncr2820680509%3E3.0.co;2-2 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/1833042/ PubMed] |
[[Category:Pancreatic cancer regimens]] | [[Category:Pancreatic cancer regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Gastrointestinal cancers]] | [[Category:Gastrointestinal cancers]] | ||
[[Category:Historical regimens]] | [[Category:Historical regimens]] |
Latest revision as of 23:34, 15 July 2024
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the main pancreatic cancer page for current regimens.
3 regimens on this page
3 variants on this page
|
Induction therapy for locally advanced disease, unresectable
FLEC
FLEC: Fluorouracil, Leucovorin (Folinic acid), Epirubicin, Carboplatin
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Cantore et al. 2004 | 1997-2001 | Phase 3 (E-esc) | Gemcitabine | Seems to have superior OS (primary endpoint) |
Chemotherapy
- Fluorouracil (5-FU) 1000 mg/m2 IA bolus once on day 1
- Leucovorin (Folinic acid) 100 mg/m2 IA bolus once on day 1
- Epirubicin (Ellence) 60 mg/m2 IA bolus once on day 1
- Carboplatin (Paraplatin) 300 mg/m2 IA bolus once on day 1
21-day cycle for 3 cycles
References
- Cantore M, Fiorentini G, Luppi G, Rosati G, Caudana R, Piazza E, Comella G, Ceravolo C, Miserocchi L, Mambrini A, Del Freo A, Zamagni D, Rabbi C, Marangolo M. Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology. J Chemother. 2004 Dec;16(6):589-94. link to original article dosing details in abstract have been reviewed by our editors PubMed
Metastatic disease, first-line
PEFG
PEFG: Platinol (Cisplatin), Epirubicin, Fluorouracil, Gemcitabine
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Reni et al. 2005 | 2000-2003 | Phase 3 (E-esc) | Gemcitabine | Superior PFS4 (primary endpoint) PFS4: 60% vs 28% (HR 0.46, 95% CI 0.26-0.79) |
Chemotherapy
- Cisplatin (Platinol) 40 mg/m2 IV once on day 1
- Epirubicin (Ellence) 40 mg/m2 IV once on day 1
- Fluorouracil (5-FU) 200 mg/m2/day IV continuous infusion over 28 days, started on day 1 (total dose per cycle: 5600 mg/m2)
- Gemcitabine (Gemzar) 600 mg/m2 IV over 60 minutes once per day on days 1 & 8
28-day cycles
References
- Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli L, Bordonaro R, Passardi A, Zerbi A, Balzano G, Aldrighetti L, Staudacher C, Villa E, Di Carlo V. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol. 2005 Jun;6(6):369-76. link to original article dosing details in abstract have been reviewed by our editors PubMed
Metastatic disease, all lines of therapy
SMF
SMF: Streptozotocin, Mitomycin, 5-Fluorouracil
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Kelsen et al. 1991 | 1987-1989 | Phase 3 (C) | CAC | Superior OS |
Chemotherapy
- Streptozocin (Zanosar) 1000 mg/m2 IV once per day on days 1, 8, 29, 36
- Mitomycin (Mutamycin) 10 mg/m2 IV once on day 1
- Fluorouracil (5-FU) 600 mg/m2 IV once per day on days 1, 8, 29, 36
8-week cycles
References
- Kelsen D, Hudis C, Niedzwiecki D, Dougherty J, Casper E, Botet J, Vinciguerra V, Rosenbluth R. A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer. 1991 Sep 1;68(5):965-9. link to original article dosing details in manuscript have been reviewed by our editors PubMed